{
    "xml": "<topic id=\"PHP97242\" outputclass=\"drug\" rev=\"1.25\" type=\"drug\" namespace=\"/drugs/alemtuzumab\" basename=\"alemtuzumab\" title=\"ALEMTUZUMAB\">\n<title>ALEMTUZUMAB</title>\n<body>\n<data name=\"vtmid\">391632007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_402717286\" title=\"Monoclonal antibodies (anti-lymphocyte)\">Monoclonal antibodies (anti-lymphocyte)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP97257\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/alemtuzumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97266\" outputclass=\"unlicensedUse\" rev=\"1.13\" parent=\"/drugs/alemtuzumab\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Although no longer licensed for oncological and transplant indications, alemtuzumab is also available through a patient access programme for these indications.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97253\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/alemtuzumab\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Alemtuzumab should be given under the care of a specialist with facilities for the management of hypersenstivity and anaphylactic reactions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97252\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/alemtuzumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Human immunodeficiency virus</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97250\" outputclass=\"cautions\" rev=\"1.36\" parent=\"/drugs/alemtuzumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Hepatitis B carriers</ph>; <ph outputclass=\"caution\">hepatitis C carriers</ph>; <ph outputclass=\"caution\">in patients with active infection, a delay in initiation of alemtuzumab treatment should be considered until the infection is fully controlled</ph>; <ph outputclass=\"caution\">not recommended for inactive disease</ph>; <ph outputclass=\"caution\">not recommended for stable disease</ph>; <ph outputclass=\"caution\">patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course</ph>; <ph outputclass=\"caution\">patients with previous autoimmune conditions other than multiple sclerosis</ph>; <ph outputclass=\"caution\">pretreatment before administration is required (consult product literature)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>For full details of cautions, consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Autoimmune mediated conditions</p>\n<p>The risk of autoimmune mediated conditions may increase during treatment, including immune thrombocytopenic purpura, thyroid disorders, nephropathies, and cytopenias, and should be monitored for throughout the course of treatment (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97258\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/alemtuzumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appenidx 1 (alemtuzumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97263\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/alemtuzumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For full side effects details (including monitoring and management) consult product literature</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97251\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/alemtuzumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Women of childbearing potential should use effective contraception during and for 4 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97259\" outputclass=\"pregnancy\" parent=\"/drugs/alemtuzumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p>\n<p>Autoimmune thyroid disease during treatment may affect fetus (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97249\" outputclass=\"breastFeeding\" parent=\"/drugs/alemtuzumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid during and for 4 months after each treatment course unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97262\" outputclass=\"preTreatmentScreening\" rev=\"1.23\" parent=\"/drugs/alemtuzumab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>Screening patients at high risk of hepatitis B or C is recommended before treatment.</p>\n<p>All patients should be evaluated for active or latent tuberculosis before starting treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97267\" outputclass=\"monitoringRequirements\" parent=\"/drugs/alemtuzumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"patientMonitoringProgrammes\">\n<sectiondiv>\n<p>HPV screening should be carried out annually in female patients.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97271\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/alemtuzumab\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>All patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97260\" outputclass=\"patientAndCarerAdvice\" rev=\"1.9\" parent=\"/drugs/alemtuzumab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p outputclass=\"title\">Alert card</p>\n<p>Patients should be provided with a Patient Alert Card and Patient Guide.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP97270\" outputclass=\"nationalFunding\" rev=\"1.19\" parent=\"/drugs/alemtuzumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA312</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Alemtuzumab for treating relapsing-remitting multiple sclerosis (May 2014)</p>\r\n<p>Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing-remitting multiple sclerosis.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA312\">www.nice.org.uk/TA312</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP97242-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/alemtuzumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP97383\" title=\"Solution for infusion\" namespace=\"/drugs/alemtuzumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" count=\"1\" rel=\"link\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP97383\" namespace=\"/drugs/alemtuzumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP97242",
    "outputclass": "drug",
    "rev": "1.25",
    "type": "drug",
    "namespace": "/drugs/alemtuzumab",
    "basename": "alemtuzumab",
    "title": "ALEMTUZUMAB",
    "vtmid": "391632007",
    "drugClassification": [
        "Monoclonal antibodies (anti-lymphocyte)"
    ],
    "inheritsFromClass": [
        "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features",
                        "html": "Treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Although no longer licensed for oncological and transplant indications, alemtuzumab is also available through a patient access programme for these indications.",
                "html": "<p>Although no longer licensed for oncological and transplant indications, alemtuzumab is also available through a patient access programme for these indications.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Alemtuzumab should be given under the care of a specialist with facilities for the management of hypersenstivity and anaphylactic reactions.",
                "html": "<p>Alemtuzumab should be given under the care of a specialist with facilities for the management of hypersenstivity and anaphylactic reactions.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Human immunodeficiency virus",
                "html": "Human immunodeficiency virus"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Hepatitis B carriers",
                "html": "Hepatitis B carriers"
            },
            {
                "type": "cautions",
                "textContent": "hepatitis C carriers",
                "html": "hepatitis C carriers"
            },
            {
                "type": "cautions",
                "textContent": "in patients with active infection, a delay in initiation of alemtuzumab treatment should be considered until the infection is fully controlled",
                "html": "in patients with active infection, a delay in initiation of alemtuzumab treatment should be considered until the infection is fully controlled"
            },
            {
                "type": "cautions",
                "textContent": "not recommended for inactive disease",
                "html": "not recommended for inactive disease"
            },
            {
                "type": "cautions",
                "textContent": "not recommended for stable disease",
                "html": "not recommended for stable disease"
            },
            {
                "type": "cautions",
                "textContent": "patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course",
                "html": "patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course"
            },
            {
                "type": "cautions",
                "textContent": "patients with previous autoimmune conditions other than multiple sclerosis",
                "html": "patients with previous autoimmune conditions other than multiple sclerosis"
            },
            {
                "type": "cautions",
                "textContent": "pretreatment before administration is required (consult product literature)",
                "html": "pretreatment before administration is required (consult product literature)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For full details of cautions, consult product literature.",
                "html": "<p>For full details of cautions, consult product literature.</p>"
            },
            {
                "type": "importantAdvice",
                "title": "Autoimmune mediated conditions",
                "textContent": "The risk of autoimmune mediated conditions may increase during treatment, including immune thrombocytopenic purpura, thyroid disorders, nephropathies, and cytopenias, and should be monitored for throughout the course of treatment (consult product literature).",
                "html": "<p>The risk of autoimmune mediated conditions may increase during treatment, including immune thrombocytopenic purpura, thyroid disorders, nephropathies, and cytopenias, and should be monitored for throughout the course of treatment (consult product literature).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appenidx 1 (alemtuzumab).",
                "html": "<p>Appenidx 1 (alemtuzumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "textContent": "For full side effects details (including monitoring and management) consult product literature",
                "html": "<p>For full side effects details (including monitoring and management) consult product literature</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Women of childbearing potential should use effective contraception during and for 4 months after treatment.",
                "html": "<p>Women of childbearing potential should use effective contraception during and for 4 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in animal studies.\n\nAutoimmune thyroid disease during treatment may affect fetus (consult product literature).",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p><p>Autoimmune thyroid disease during treatment may affect fetus (consult product literature).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid during and for 4 months after each treatment course unless potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises avoid during and for 4 months after each treatment course unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "Screening patients at high risk of hepatitis B or C is recommended before treatment.\n\nAll patients should be evaluated for active or latent tuberculosis before starting treatment.",
                "html": "<p>Screening patients at high risk of hepatitis B or C is recommended before treatment.</p><p>All patients should be evaluated for active or latent tuberculosis before starting treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientMonitoringProgrammes": [
            {
                "type": "patientMonitoringProgrammes",
                "textContent": "HPV screening should be carried out annually in female patients.",
                "html": "<p>HPV screening should be carried out annually in female patients.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "All patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course.",
                "html": "<p>All patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "title": "Alert card",
                "textContent": "Patients should be provided with a Patient Alert Card and Patient Guide.",
                "html": "<p>Patients should be provided with a Patient Alert Card and Patient Guide.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA312",
                        "label": "www.nice.org.uk/TA312"
                    }
                ],
                "fundingIdentifier": "NICE TA312",
                "textContent": "Alemtuzumab for treating relapsing-remitting multiple sclerosis (May 2014) Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing-remitting multiple sclerosis.\n\nwww.nice.org.uk/TA312",
                "html": "<p outputclass=\"title\">Alemtuzumab for treating relapsing-remitting multiple sclerosis (May 2014)</p> <p>Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing-remitting multiple sclerosis.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA312\">www.nice.org.uk/TA312</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP97383",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34582",
                "label": "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP97383",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}